Enabling Acceleration & Risk Mitigation in Advanced Therapy Medicinal Product (ATMP) Development & Beyond
July 23, 2024
In the evolving landscape of Advanced Therapy Medicinal Products (ATMPs), the potential to address a multitude of diseases, including rare disorders, is underscored by significant advancements.
With 17 gene therapies approved in the United States in 2023 and anticipation of a breakout year in 2024 for cell and gene therapies, particularly targeting rare disorders, the urgency to overcome hurdles is evident (Source: https://alliancerm.org/arm-event/sotibriefing/). Embracing proactive risk mitigation strategies and fostering collaborative ecosystems are essential to propel the translation of scientific discoveries into transformative therapies, shaping a brighter future for medicine and patient care.
In Azzur Group's new whitepaper, you will gain an understanding of dynamic solutions to help navigate manufacturing complexities and accelerate ATMP development.